Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Hasbro, Inc. (HAS) Price & Performance

Ascendis Pharma A/STrade
Hasbro, Inc.Trade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Hasbro, Inc. — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Hasbro, Inc. trades at $97.28 (market cap $13.33B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Hasbro, Inc. pays a 2.96% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.

ASNDHAS
Market Cap
$16.78B$13.33B
Sector
HealthConsumer Cyclical
52-Week High
$277.18$105.88
52-Week Low
$189.74$70.95
Enterprise Value
$17.15B$15.52B
Dividend Yield
2.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.

ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.

Hasbro, Inc.

Hasbro (HAS) trades at $93.52, up 2.0% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth driven by Magic: The Gathering and digital gaming, though net income turned negative in 2025. Analyst consensus is a Buy with a $104.90 price target, supported by institutional accumulation and positive media coverage on franchise strength.

Outlook remains positive with 2026 revenue projected at $5.0B and net income of $794M, but risks include high debt levels, margin pressures from tariffs, and cybersecurity concerns. The stock offers a 2.93% dividend yield, with upside potential if growth sustains, yet volatility may persist amid cost headwinds.

Returns comparison

Trailing returns across standard periods

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Hasbro, Inc.

Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.

Read more on HAS